California Healthline senior correspondent Angela Hart describes California’s ambitious plan to manufacture generic insulin under the state’s new “CalRx” drug label.
Editas Medicine has confirmed that a cell therapy for sickle cell disease has successfully engrafted into the first patient dosed in a phase 1/2 trial, which means—for those of us without a science degree—the therapy has been accepted by the patient’s body and is starting to create new blood cells as planned.
Some Japanese insurance companies are taking advantage of the situation, offering daily coverage for consumers who are worried about heat stroke.
When it comes to prescription drugs lowest premium and lowest cost aren’t always the same thing.
The Coalition for Epidemic Preparedness Innovations will provide funding up to $375,000 to support the development of laboratory tools to assess monkeypox vaccines.
New medical innovations provides glimmer of hope for the development of complex kidney organoids that can be used as a substitute for kidney transplants.
The US Food and Drug Administration is relaxing its unique device identified (UDI) rule requirements for low-risk class I consumer health products. Other class I and unclassified devices will still need to follow UDI requirements, though FDA announced it will extend its compliance deadline for those devices to 8 December 2022.
Use of computational software in drug research is growing, and some big tech companies are angling for a piece of this market. Cadence Design Systems is entering the life sciences sector through the $500 million acquisition of OpenEye Scientific, a company that provides computational drug design software to the pharmaceutical industry.
Contraception legislation follows effort to protect same-sex and interracial marriage.
The bill to allow Medicare to negotiate some drug prices, cap out-of-pocket drug costs for seniors, and extend temporary subsidies for Affordable Care Act insurance premiums would represent a major step if Democrats can get it across the finish line.
Families scramble to find support for their children after, without any warning, services were disrupted.
Financial analysis of Elevance Health, formerly known as Anthem, and the rising revenues for the quarter, which is attributed to increased enrollment.
There are signs that rising inflation could impact biotech’s outlook into the second half of the year.
Fold Health, a new startup, has launched programming for primary care in the form of digital health
This website uses cookies and similar technologies to understand visitor experiences. By using this website, you consent to UNC-Chapel Hill's cookie usage in accordance with their Privacy Notice.
